PL1609785T3 - Pochodne c-glikozydowe i ich sole - Google Patents

Pochodne c-glikozydowe i ich sole

Info

Publication number: PL1609785T3
Authority: PL; Poland
Prior art keywords: diabetes; salts; insulin; ring; glycoside derivatives
Prior art date: 2003-03-14

Application number

PL04720254T

Other languages

English (en)

Inventor

Masakazu Imamura

Takeshi Murakami

Ryota Shiraki

Kazuhiro Ikegai

Takashi Sugane

Fumiyoshi Iwasaki

Eiji Kurosaki

Hiroshi Tomiyama

Atsushi Noda

Kayoko Kitta

Yoshinori Kobayashi

Original Assignee

Astellas Pharma Inc

Kotobuki Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-14

Filing date

2004-03-12

Publication date

2016-07-29

2004-03-12 Application filed by Astellas Pharma Inc, Kotobuki Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc

2016-07-29 Publication of PL1609785T3 publication Critical patent/PL1609785T3/pl

Links

229930182476 C-glycoside Natural products 0.000 title abstract 2
150000000700 C-glycosides Chemical class 0.000 title abstract 2
150000003839 salts Chemical class 0.000 title abstract 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
206010012601 diabetes mellitus Diseases 0.000 abstract 3
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 2
201000010099 disease Diseases 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
102000034534 Cotransporters Human genes 0.000 abstract 1
108020003264 Cotransporters Proteins 0.000 abstract 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000008103 glucose Substances 0.000 abstract 1
125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
230000003449 preventive effect Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Hematology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Pyrane Compounds (AREA)

PL04720254T 2003-03-14 2004-03-12 Pochodne c-glikozydowe i ich sole PL1609785T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2003070297		2003-03-14
EP04720254.4A EP1609785B1 (en)	2003-03-14	2004-03-12	C-glycoside derivatives and salts thereof
PCT/JP2004/003324 WO2004080990A1 (ja)	2003-03-14	2004-03-12	Ｃ－グリコシド誘導体又はその塩

Publications (1)

Publication Number	Publication Date
PL1609785T3 true PL1609785T3 (pl)	2016-07-29

Family

ID=32984648

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL04720254T PL1609785T3 (pl)	2003-03-14	2004-03-12	Pochodne c-glikozydowe i ich sole
PL08012499T PL1980560T3 (pl)	2003-03-14	2004-03-12	Pochodne C-glikozydowe do leczenia cukrzycy

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL08012499T PL1980560T3 (pl)	2003-03-14	2004-03-12	Pochodne C-glikozydowe do leczenia cukrzycy

Country Status (19)

Country	Link
US (3)	US7202350B2 (pl)
EP (2)	EP1609785B1 (pl)
JP (2)	JP4222450B2 (pl)
KR (2)	KR101001850B1 (pl)
CN (1)	CN1802366B (pl)
AT (1)	ATE510834T1 (pl)
AU (2)	AU2004220222B2 (pl)
BR (1)	BRPI0408140B8 (pl)
CA (1)	CA2526145C (pl)
ES (2)	ES2567571T3 (pl)
MX (1)	MXPA05009356A (pl)
NO (1)	NO334799B1 (pl)
NZ (1)	NZ542399A (pl)
PL (2)	PL1609785T3 (pl)
PT (1)	PT1980560E (pl)
RU (1)	RU2317288C3 (pl)
TW (2)	TWI309980B (pl)
WO (1)	WO2004080990A1 (pl)
ZA (1)	ZA200507754B (pl)

Families Citing this family (200)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
PL1609785T3 (pl)	2003-03-14	2016-07-29	Astellas Pharma Inc	Pochodne c-glikozydowe i ich sole
SG130189A1 (en)	2003-08-01	2007-03-20	Janssen Pharmaceutica Nv	Substituted indole-o-glucosides
US8785403B2 (en)	2003-08-01	2014-07-22	Mitsubishi Tanabe Pharma Corporation	Glucopyranoside compound
EA011515B1 (ru)	2003-08-01	2009-04-28	Янссен Фармацевтика Н.В.	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
EP1679965A4 (en)	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
WO2005012326A1 (en) *	2003-08-01	2005-02-10	Tanabe Seiyaku Co., Ltd.	Novel compounds having inhibitory activity against sodium-dependant transporter
RS20060320A (sr)	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Supstituisani indazol-o-glukozidi
NZ549219A (en) *	2004-03-04	2010-08-27	Kissei Pharmaceutical	Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
CA2557269C (en) *	2004-03-04	2012-12-04	Kissei Pharmaceutical Co., Ltd.	Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
CA2557801C (en)	2004-03-16	2013-06-25	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzol derivatives, drugs containing said compounds, the use thereof and method for the production thereof
US7393836B2 (en)	2004-07-06	2008-07-01	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
WO2006010557A1 (de) *	2004-07-27	2006-02-02	Boehringer Ingelheim International Gmbh	D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) *	2004-08-11	2006-02-23	Boehringer Ingelheim International Gmbh	D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CA2581922A1 (en) *	2004-09-29	2006-04-06	Kissei Pharmaceutical Co., Ltd.	1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
DE102004048388A1 (de) *	2004-10-01	2006-04-06	Boehringer Ingelheim Pharma Gmbh & Co. Kg	D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1813611B1 (en) *	2004-11-18	2014-10-01	Kissei Pharmaceutical Co., Ltd.	1-substituted-3- beta-d-glycopyranosylated nitrogenous hetero- cyclic compounds and medicines containing the same
TW200635599A (en) *	2004-12-16	2006-10-16	Boehringer Ingelheim Int	Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200637839A (en)	2005-01-07	2006-11-01	Taisho Pharmaceutical Co Ltd	1-thio-d-glucitol derivatives
TW200637869A (en)	2005-01-28	2006-11-01	Chugai Pharmaceutical Co Ltd	The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP4496174B2 (ja) *	2005-01-31	2010-07-07	田辺三菱製薬株式会社	医薬組成物
TWI365186B (en)	2005-01-31	2012-06-01	Mitsubishi Tanabe Pharma Corp	Indole derivatives
ATE445608T1 (de) *	2005-02-23	2009-10-15	Boehringer Ingelheim Int	Glucopyranosylsubstituierte ((hetero)arylethynyl- benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose- cotransporters typ 2 (sglt2)
EP1874787B1 (en) *	2005-04-15	2009-12-30	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted (heteroaryloxy-benzyl)-benzene derivatives as sglt inhibitors
UA91546C2 (uk) *	2005-05-03	2010-08-10	Бьорінгер Інгельхайм Інтернаціональ Гмбх	КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7723309B2 (en)	2005-05-03	2010-05-25	Boehringer Ingelheim International Gmbh	Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
US7772191B2 (en) *	2005-05-10	2010-08-10	Boehringer Ingelheim International Gmbh	Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
WO2007000445A1 (en) *	2005-06-29	2007-01-04	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
TW200726755A (en) *	2005-07-07	2007-07-16	Astellas Pharma Inc	A crystalline choline salt of an azulene derivative
EP1910390B1 (en) *	2005-07-27	2010-05-19	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted ((hetero)cycloalyklethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter (sglt) inhibitors
DE602006017566D1 (de)	2005-08-30	2010-11-25	Boehringer Ingelheim Pharma	Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
ES2358051T3 (es)	2005-09-08	2011-05-05	Boehringer Ingelheim International Gmbh	Formas cristalinas de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-etinil-bencil)-benceno, métodos para su preparación y su uso para preparar medicamentos.
AR056195A1 (es) *	2005-09-15	2007-09-26	Boehringer Ingelheim Int	Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AU2007216452A1 (en)	2006-02-15	2007-08-23	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
TWI370818B (en)	2006-04-05	2012-08-21	Astellas Pharma Inc	Cocrystal of c-glycoside derivative and l-proline
PE20080697A1 (es)	2006-05-03	2008-08-05	Boehringer Ingelheim Int	Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20110235A1 (es)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
AR061026A1 (es) *	2006-05-19	2008-07-30	Taisho Pharmaceutical Co Ltd	Compuesto glicitol c-fenilo y preparacion farmaceutica
US7803778B2 (en) *	2006-05-23	2010-09-28	Theracos, Inc.	Glucose transport inhibitors and methods of use
US7919598B2 (en) *	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
TWI432446B (zh)	2006-07-27	2014-04-01	Chugai Pharmaceutical Co Ltd	稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI418556B (zh)	2006-07-27	2013-12-11	Mitsubishi Tanabe Pharma Corp	吲哚衍生物
TWI403516B (zh)	2006-07-27	2013-08-01	Chugai Pharmaceutical Co Ltd	To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
US20080027014A1 (en) *	2006-07-28	2008-01-31	Tanabe Seiyaku Co., Ltd.	Novel SGLT inhibitors
EP2054426A1 (en)	2006-08-15	2009-05-06	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as sglt inhibitors and process for their manufacture
JP5372759B2 (ja) *	2006-09-21	2013-12-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	グルコピラノシル−置換ジフルオロベンジル−ベンゼン誘導体、該化合物を含有する医薬品及びその使用と調製方法
TWI499414B (zh) *	2006-09-29	2015-09-11	Lexicon Pharmaceuticals Inc	鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ２）的抑制物與其應用方法
EP2072522A4 (en) *	2006-10-13	2010-01-06	Chugai Pharmaceutical Co Ltd	THIOGLUCOSE SPIRKETAL DERIVATIVE AND ITS USE AS DIABETES THERAPEUTIC
EP2086991A1 (en) *	2006-10-27	2009-08-12	Boehringer Ingelheim International GmbH	CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS
WO2008070609A1 (en) *	2006-12-04	2008-06-12	Janssen Pharmaceutica N.V.	Thienyl-containing glycopyranosyl derivatives as antidiabetics
UY30730A1 (es)	2006-12-04	2008-07-03	Mitsubishi Tanabe Pharma Corp	Forma cristalina del hemihidrato de 1-(b (beta)-d-glucopiranosil) -4-metil-3-[5-(4-fluorofenil) -2-tienilmetil]benceno
WO2008075736A1 (ja)	2006-12-21	2008-06-26	Astellas Pharma Inc.	Ｃ－グリコシド誘導体の製造方法及びその合成中間体
US7795228B2 (en) *	2006-12-28	2010-09-14	Theracos, Inc.	Spiroheterocyclic glycosides and methods of use
WO2008109591A1 (en) *	2007-03-08	2008-09-12	Lexicon Pharmaceuticals, Inc.	Phlorizin analogs as inhibitors of sodium glucose co-transporter 2
TW200904454A (en)	2007-03-22	2009-02-01	Bristol Myers Squibb Co	Methods for treating obesity employing an SGLT2 inhibitor and compositions thereof
CN101652377A (zh) *	2007-04-02	2010-02-17	泰拉科斯有限公司	苄基化糖苷衍生物及其用法
CN103254119B (zh) *	2007-07-10	2016-07-06	莱西肯医药有限公司	钠-葡萄糖协同转运蛋白2的抑制剂及其用法
EP2183263B1 (en)	2007-07-26	2011-10-26	Lexicon Pharmaceuticals, Inc.	Methods and compounds useful for the preparation of sodium glucose co-transporter 2 inhibitors
CL2008002425A1 (es) *	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composición farmacéutica que comprende un inhibidor de sglt2 y 1-(4-metil-quinazolin-2-il)metil-3metil-7-(-2-butin-1-il)-8-(3-(r)-amino-piperidin-1il)-xantina, un inhibidor de dpp iv y su uso para el tratamiento de la obesidad y de la diabetes tipo 1 y 2 y complicaciones de esta.
CL2008002427A1 (es)	2007-08-16	2009-09-11	Boehringer Ingelheim Int	Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
US7838499B2 (en) *	2007-08-23	2010-11-23	Theracos, Inc.	Benzylbenzene derivatives and methods of use
NZ600110A (en) *	2007-09-10	2013-03-28	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt
AU2008326309C1 (en) *	2007-11-21	2015-03-12	Decode Genetics Ehf	Biaryl PDE4 inhibitors for treating pulmonary and cardiovascular disorders
UA101004C2 (en)	2007-12-13	2013-02-25	Теракос, Инк.	Derivatives of benzylphenylcyclohexane and use thereof
CL2008003653A1 (es)	2008-01-17	2010-03-05	Mitsubishi Tanabe Pharma Corp	Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
EP2236137B1 (en) *	2008-01-31	2015-06-24	Astellas Pharma Inc.	Pharmaceutical composition for treatment of fatty liver diseases
TW201000494A (en) *	2008-02-13	2010-01-01	Sanofi Aventis	Novel aromatic fluoroglycoside derivatives, medicaments comprising these compounds and use thereof
DE102008017590A1 (de) *	2008-04-07	2009-10-08	Merck Patent Gmbh	Glucopyranosidderivate
JP5820269B2 (ja)	2008-05-22	2015-11-24	アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａＡｋｔｉｅｂｏｌａｇ	Ｓｇｌｔ２阻害剤を使用する高尿酸血症の治療方法およびｓｇｌｔ２阻害剤を含有する組成物
ME02702B (me)	2008-08-22	2017-10-20	Theracos Sub Llc	Postupci za pripremu inhibitora sgl t2
AP2728A (en) *	2008-08-28	2013-08-31	Pfizer	Dioxa-bicyclo[3.2.1.] octane-2,3,4-triol derivatives
EA201100503A1 (ru) *	2008-09-19	2011-10-31	Новартис Аг	Глюкозидные производные и их применения
US9056850B2 (en) *	2008-10-17	2015-06-16	Janssen Pharmaceutica N.V.	Process for the preparation of compounds useful as inhibitors of SGLT
WO2010074219A1 (ja) *	2008-12-26	2010-07-01	アステラス製薬株式会社	ベンゾチオフェン化合物
HUE050287T2 (hu)	2009-02-13	2020-11-30	Boehringer Ingelheim Int	SGLT2-inhibitort, DPP-IV-inhibitort és adott esetben egy további antidiabetikus hatóanyagot tartalmazó gyógyászati készítmény és alkalmazásai
CN102387783A (zh) *	2009-02-13	2012-03-21	贝林格尔.英格海姆国际有限公司	包含吡喃葡萄糖基二苯基甲烷衍生物的药物组合物、其药物剂型、其制备方法及其在患者中改善血糖控制的用途
EP4684831A3 (en)	2009-02-13	2026-03-11	Boehringer Ingelheim International GmbH	Sglt2 inhibitor for improving glycemic control
MY155658A (en) *	2009-02-23	2015-11-13	Taisho Pharmaceutical Co Ltd	A-isopropylphenyl glucitol compounds as sglti inhibitors
US20110009347A1 (en)	2009-07-08	2011-01-13	Yin Liang	Combination therapy for the treatment of diabetes
US8772512B2 (en)	2009-07-10	2014-07-08	Janssen Pharmaceutica Nv	Crystallisation process for 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl] benzene
BR112012007085B8 (pt)	2009-09-30	2021-05-25	Boehringer Ingelheim Int	processos para a preparação de derivados de benzil-benzeno substituídos com glicopiranosila
NZ598318A (en) *	2009-09-30	2014-02-28	Boehringer Ingelheim Int	Method for the preparation of a crystalline form of 1-chloro-4- (beta-d-glucopyranos-1-yl)-2-(4-((s)-tetrahydrofuran-3-yloxy)benzyl)benzene
UY32919A (es)	2009-10-02	2011-04-29	Boehringer Ingelheim Int	Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
PH12012500698A1 (en) *	2009-10-14	2016-05-27	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt2
WO2011048148A2 (en) *	2009-10-20	2011-04-28	Novartis Ag	Glycoside derivative and uses thereof
US8163704B2 (en) *	2009-10-20	2012-04-24	Novartis Ag	Glycoside derivatives and uses thereof
RU2012121183A (ru) *	2009-10-23	2013-11-27	Астеллас Фарма Инк.	Фармацевтическая композиция для перорального введения
DK2496583T3 (en)	2009-11-02	2015-02-02	Pfizer	Dioxa-bicyclo [3.2.1] octane-2,3,4-triol DERIVATIVES
WO2011070592A2 (en)	2009-12-09	2011-06-16	Panacea Biotec Ltd.	Novel sugar derivatives
CN102134226B (zh) *	2010-01-26	2013-06-12	天津药物研究院	一类苯基c-葡萄糖苷衍生物、其制备方法和用途
CN102146066A (zh) *	2010-02-05	2011-08-10	天津药物研究院	一类含饱和六元环的c-葡萄糖苷衍生物、其制备方法和用途
US8575114B2 (en)	2010-03-23	2013-11-05	Albany Molecular Research, Inc.	SGLT-2 inhibitors, methods of making them, and uses thereof
WO2011127051A1 (en)	2010-04-06	2011-10-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
ES2596291T3 (es)	2010-05-11	2017-01-05	Janssen Pharmaceutica, N.V.	Formulaciones farmacéuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
WO2011153712A1 (en)	2010-06-12	2011-12-15	Theracos, Inc.	Crystalline form of benzylbenzene sglt2 inhibitor
JP2012001515A (ja) *	2010-06-21	2012-01-05	Toyama Univ	グリコーゲン分解酵素阻害剤
CN102372722A (zh) *	2010-08-10	2012-03-14	江苏恒瑞医药股份有限公司	C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
WO2012025857A1 (en)	2010-08-23	2012-03-01	Hetero Research Foundation	Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
WO2012033390A2 (en) *	2010-09-10	2012-03-15	Green Cross Corporation	Novel thiophene derivative as sglt2 inhibitor and pharmaceutical composition comprising same
SG188548A1 (en)	2010-09-22	2013-04-30	Arena Pharm Inc	Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2012041898A1 (en)	2010-09-29	2012-04-05	Celon Pharma Sp. Z O.O.	Combination of sglt2 inhibitor and a sugar compound for the treatment of diabetes
US20120283169A1 (en)	2010-11-08	2012-11-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US20130035281A1 (en)	2011-02-09	2013-02-07	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
WO2012109996A1 (zh)	2011-02-18	2012-08-23	上海璎黎科技有限公司	一种芳基糖苷类化合物及其制备方法和应用
AR085689A1 (es)	2011-03-07	2013-10-23	Boehringer Ingelheim Int	Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
WO2012135570A1 (en)	2011-04-01	2012-10-04	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN103596944B (zh)	2011-04-13	2017-02-22	詹森药业有限公司	可用作sglt2的抑制剂的化合物的制备方法
US8614195B2 (en) *	2011-04-14	2013-12-24	Novartis Ag	Glycoside derivatives and uses thereof
CA2832951A1 (en) *	2011-04-14	2012-10-18	Novartis Ag	Glycoside derivatives and uses thereof
US20140066369A1 (en)	2011-04-19	2014-03-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140051714A1 (en)	2011-04-22	2014-02-20	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
US20140038889A1 (en)	2011-04-22	2014-02-06	Arena Pharmaceuticals, Inc.	Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto
WO2012144592A1 (ja) *	2011-04-22	2012-10-26	アステラス製薬株式会社	固形医薬組成物
US9035044B2 (en)	2011-05-09	2015-05-19	Janssen Pharmaceutica Nv	L-proline and citric acid co-crystals of (2S, 3R, 4R, 5S,6R)-2-(3-((5-(4-fluorophenyl)thiopen-2-yl)methyl)4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol
WO2012162115A2 (en)	2011-05-20	2012-11-29	Janssen Pharmaceutica Nv	Process for the preparation of compounds useful as inhibitors of sglt-2
US20130137646A1 (en)	2011-06-03	2013-05-30	Boehringer Ingelheim International Gmbh	Methods of treatment, pharmaceutical compositions and uses thereof
WO2012170702A1 (en)	2011-06-08	2012-12-13	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102863417B (zh) *	2011-07-09	2015-01-14	山东轩竹医药科技有限公司	C-糖苷衍生物
WO2013038429A2 (en)	2011-09-13	2013-03-21	Panacea Biotec Ltd.	Novel sglt inhibitors
EP2573088A1 (en) *	2011-09-26	2013-03-27	Prous Institute for Biomedical Research, S.A.	Pyrano[3,2-c]benzopyran-6(2h)-one derivatives and uses thereof
CN102408459B (zh) *	2011-09-29	2014-07-23	天津药物研究院	一类含异头位烷基的苯基c-葡萄糖苷衍生物、其制备方法和用途
WO2013055910A1 (en)	2011-10-12	2013-04-18	Arena Pharmaceuticals, Inc.	Modulators of the gpr119 receptor and the treatment of disorders related thereto
CN102516215B (zh) *	2011-12-12	2014-04-09	天津药物研究院	含饱和环己烷结构的c-葡萄糖苷的制备方法
CN103508989A (zh) *	2011-12-12	2014-01-15	天津药物研究院	一种(1s)-1,6-二脱氧-1-[4-羟基-3-(反式-4-取代环己基)甲基苯基]-d-吡喃葡萄糖化合物的制备方法
CN103524469A (zh) *	2011-12-12	2014-01-22	天津药物研究院	一种(1s)-1,6-二脱氧-1-[4-羟基-3-(反式-4-取代环己基)甲基苯基]-d-吡喃葡萄糖化合物及其制备方法
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
US9192617B2 (en)	2012-03-20	2015-11-24	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US9193751B2 (en)	2012-04-10	2015-11-24	Theracos, Inc.	Process for the preparation of benzylbenzene SGLT2 inhibitors
WO2013152476A1 (en) *	2012-04-10	2013-10-17	Theracos, Inc.	Process for the preparation of benzylbenzene sglt2 inhibitors
WO2014074668A1 (en)	2012-11-08	2014-05-15	Arena Pharmaceuticals, Inc.	Modulators of gpr119 and the treatment of disorders related thereto
EP2933250B1 (en)	2012-12-17	2017-08-09	Tianjin Institute Of Pharmaceutical Research	Phenyl c-glucoside derivative containing deoxyglucose structure, preparation method and use thereof
CN103910769B (zh)	2012-12-31	2018-10-02	上海璎黎药业有限公司	葡萄糖衍生物和脯氨酸的复合物、晶体、制备方法及应用
WO2014164286A1 (en) *	2013-03-11	2014-10-09	Janssen Pharmaceutica Nv	Dual sglt1/sglt2 inhibitors
WO2014159151A1 (en)	2013-03-14	2014-10-02	Msd International Gmbh	Methods for preparing sglt2 inhibitors
PT2981269T (pt)	2013-04-04	2023-10-10	Boehringer Ingelheim Vetmedica Gmbh	Tratamento de distúrbios metabólicos em animais equinos
CA2812519A1 (en)	2013-04-05	2014-10-05	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en)	2013-04-05	2023-11-14	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
TR201901110T4 (tr)	2013-04-05	2019-02-21	Boehringer Ingelheim Int	Empagliflozinin terapötik kullanımları.
US20140303097A1 (en)	2013-04-05	2014-10-09	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (zh)	2013-04-18	2016-08-26	勃林格殷格翰国际有限公司	药物组合物、治疗方法及其用途
JP5646706B2 (ja) *	2013-07-24	2014-12-24	壽製薬株式会社	Ｃ−グリコシド誘導体の製造方法
WO2015051484A1 (en)	2013-10-12	2015-04-16	Theracos, Inc.	Preparation of hydroxy-benzylbenzene derivatives
CN105828815B (zh)	2013-12-17	2020-03-27	勃林格殷格翰动物保健有限公司	猫科动物中代谢紊乱的治疗
PL3485890T3 (pl)	2014-01-23	2023-08-28	Boehringer Ingelheim Vetmedica Gmbh	Inhibitory SGLT2 do leczenia zaburzeń metabolicznych u zwierząt psowatych
KR102662473B1 (ko)	2014-04-01	2024-05-03	베링거잉겔하임베트메디카게엠베하	말과 동물에서 대사 장애의 치료
CN105001213B (zh)	2014-04-14	2020-08-28	上海迪诺医药科技有限公司	C-芳基糖苷衍生物、其药物组合物、制备方法及应用
TW201623321A (zh) *	2014-05-13	2016-07-01	韓美藥品股份有限公司	雙環衍生物及包含其之藥學組成物
CN107108539A (zh) *	2014-09-15	2017-08-29	北京生命科学研究所	钠‑葡萄糖协同转运蛋白2(sglt‑2)抑制剂
DK3197429T3 (da)	2014-09-25	2024-08-26	Boehringer Ingelheim Vetmedica Gmbh	Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
CN104478958A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含卤代联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104447907A (zh) *	2015-01-14	2015-03-25	佛山市赛维斯医药科技有限公司	含硝基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478959A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含腈基联苯双葡萄糖苷结构化合物、其制备方法和用途
CN104478957A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	一种含腈基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104530150A (zh) *	2015-01-14	2015-04-22	佛山市赛维斯医药科技有限公司	含胺基苯和双葡萄糖苷结构化合物、其制备方法和用途
CN104447905A (zh) *	2015-01-14	2015-03-25	佛山市赛维斯医药科技有限公司	一种含硝基苯和双o-葡萄糖苷衍生物、其制备方法和用途
CN104530149A (zh) *	2015-01-14	2015-04-22	佛山市赛维斯医药科技有限公司	卤代苯基双o-葡萄糖苷衍生物、其制备方法和用途
CN104447906A (zh) *	2015-01-14	2015-03-25	佛山市赛维斯医药科技有限公司	烷氧苯基双葡萄糖苷衍生物、其制备方法和用途
CN104478970A (zh) *	2015-01-14	2015-04-01	佛山市赛维斯医药科技有限公司	含苯基噻唑基的o-半乳糖苷衍生物、其制备方法和用途
CN104478964A (zh) *	2015-01-15	2015-04-01	佛山市赛维斯医药科技有限公司	含丙烯腈结构的苯o-葡萄糖苷衍生物、其制备方法和用途
WO2016128995A1 (en) *	2015-02-09	2016-08-18	Indoco Remedies Limited	Process for the preparation of sglt inhibitor compounds
CN106188022A (zh) *	2015-04-30	2016-12-07	上海医药工业研究院	伊格列净的制备方法
US20170071970A1 (en)	2015-09-15	2017-03-16	Janssen Pharmaceutica Nv	Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
WO2017141202A1 (en)	2016-02-17	2017-08-24	Lupin Limited	Complex of sglt2 inhibitor and process for preparation thereof
EP3528800A1 (en)	2016-10-19	2019-08-28	Boehringer Ingelheim International GmbH	Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
AU2017357589B2 (en)	2016-11-10	2023-05-11	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
JP7202892B2 (ja)	2017-01-11	2023-01-12	興和株式会社	非アルコール性脂肪性肝疾患の予防及び治療薬
WO2018207111A1 (en)	2017-05-09	2018-11-15	Piramal Enterprises Limited	A process for the preparation of sglt2 inhibitors and intermediates thereof
CN108017613B (zh) *	2017-12-13	2020-02-14	大连大学	钌催化杂环芳酮与二苯乙炔反应制备多芳取代萘衍生物的方法
AU2019254371A1 (en)	2018-04-17	2020-10-08	Boehringer Ingelheim International Gmbh	Pharmaceutical composition, methods for treating and uses thereof
CN110551088B (zh) *	2018-06-01	2022-10-21	北京惠之衡生物科技有限公司	氘修饰的苄基-4-氯苯基的c-糖苷衍生物
WO2020016335A1 (en)	2018-07-19	2020-01-23	Astrazeneca Ab	Methods of treating hfpef employing dapagliflozin and compositions comprising the same
WO2020039394A1 (en)	2018-08-24	2020-02-27	Novartis Ag	New drug combinations
CN112955214B (zh)	2018-10-29	2024-05-07	勃林格殷格翰国际有限公司	吡啶基磺酰胺衍生物、药物组合物及其用途
CN112955215B (zh)	2018-10-29	2024-05-17	勃林格殷格翰国际有限公司	吡啶基磺酰胺衍生物、药物组合物及其用途
WO2020151621A1 (zh) *	2019-01-24	2020-07-30	北京盈科瑞创新药物研究有限公司	化合物、其制备方法及医药用途
CN111471040B (zh) *	2019-01-24	2023-06-02	北京盈科瑞创新药物研究有限公司	一种糖苷类衍生物的合成方法及其中间体和应用
CN110054603B (zh) *	2019-05-13	2020-12-01	南开大学	一种芳基碳苷类化合物的合成方法
KR102097250B1 (ko)	2019-11-09	2020-04-03	유니셀랩 주식회사	신규한 이프라글리플로진의 결정형, 이의 제조방법 또는 용도
WO2021105152A1 (en)	2019-11-28	2021-06-03	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors in the drying-off of non-human mammals
BR112022016360A2 (pt)	2020-02-17	2022-10-04	Boehringer Ingelheim Vetmedica Gmbh	Uso de inibidores de sglt-2 para a prevenção e/ou tratamento de doenças cardíacas em felinos
US11801234B2 (en)	2020-03-06	2023-10-31	Vertex Pharmaceuticals Incorporated	Methods of treating APOL-1 dependent focal segmental glomerulosclerosis
US20230201174A1 (en)	2020-04-22	2023-06-29	Bayer Aktiengesellschaft	Combination of finerenone and a sglt2 inhibitor for the treatment and/or prevention of cardiovascular and/or renal diseases
SI4188389T1 (sl)	2020-07-27	2025-11-28	Astrazeneca Ab	Dapagliflozin za uporabo pri postopkih zdravljenja kronične ledvične bolezni
TW202220672A (zh)	2020-07-27	2022-06-01	瑞典商阿斯特捷利康公司	用達格列淨治療慢性腎臟病之方法
CN112062742B (zh) *	2020-09-22	2021-08-20	广州市力鑫药业有限公司	一种泰格列净的制备方法
KR102660615B1 (ko)	2020-10-28	2024-04-26	동방에프티엘(주)	이프라글리플로진의 신규 공결정 및 이의 제조 방법
US20240212818A1 (en)	2021-04-01	2024-06-27	Astrazeneca Uk Limited	Systems and methods for managing prediabetes with a gliflozin sodiumglucose cotransport 2 inhibitor pharmaceutical composition
EP4376829A1 (en)	2021-07-28	2024-06-05	Boehringer Ingelheim Vetmedica GmbH	Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in non-human mammals excluding felines, in particular canines
US20240269105A1 (en)	2021-07-28	2024-08-15	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of hypertension in non-human mammals
WO2023006747A1 (en)	2021-07-28	2023-02-02	Boehringer Ingelheim Vetmedica Gmbh	Use of sglt-2 inhibitors for the prevention and/or treatment of renal diseases in non-human mammals
WO2023129595A1 (en)	2021-12-30	2023-07-06	Newamsterdam Pharma B.V.	Obicetrapib and sglt2 inhibitor combination
US20250108065A1 (en)	2022-01-26	2025-04-03	Astrazeneca Ab	Methods of treating prediabetes or reducing the risk of developing type 2 diabetes with dapagliflozin
CA3256728A1 (en)	2022-05-25	2023-11-30	Boehringer Ingelheim Vetmedica Gmbh	AQUEOUS PHARMACEUTICAL COMPOSITIONS CONTAINING SGLT-2 INHIBITORS
KR102887058B1 (ko)	2022-11-08	2025-11-18	동방에프티엘(주)	이프라글리플로진의 신규한 제조 방법
TW202500160A (zh)	2023-03-06	2025-01-01	德商百靈佳殷格翰維美迪加股份有限公司	用於遞送特別是包含一或多種ｓｇｌｔ—２抑制劑之液體醫藥組合物之系統及方法
EP4701626A1 (en)	2023-04-24	2026-03-04	NewAmsterdam Pharma B.V.	Amorphous obicetrapib and sglt2 inhibitor combination
WO2024240632A1 (en)	2023-05-24	2024-11-28	Boehringer Ingelheim Vetmedica Gmbh	Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
TW202508455A (zh)	2023-05-24	2025-03-01	德商百靈佳殷格翰維美迪加股份有限公司	包含一或多種sglt-2抑制劑及替米沙坦(telmisartan)之非人類哺乳動物之腎臟疾病及/或高血壓之組合治療及/或預防
WO2025125513A1 (en)	2023-12-15	2025-06-19	AstraZeneca Ireland Limited	Sglt2 inhibitors and baxdrostat for treating chronic kidney disease and hypertension
WO2025224069A1 (en)	2024-04-23	2025-10-30	Bayer Aktiengesellschaft	Co-crystals of finerenone, pecavaptan, and sglt2 inhibitors

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1020944C (zh)	1990-01-30	1993-05-26	阿图尔-费希尔股份公司费希尔厂	紧固件
JPH06199695A (ja)	1992-03-06	1994-07-19	Yunie:Kk	糖尿病改善治療剤
AU6024998A (en) *	1997-01-15	1998-08-07	Glycomed Incorporated	Aryl c-glycoside compounds and sulfated esters thereof
JPH1121243A (ja)	1997-05-06	1999-01-26	Tanabe Seiyaku Co Ltd	医薬組成物
US6515117B2 (en)	1999-10-12	2003-02-04	Bristol-Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en)	1999-10-12	2006-02-21	Bristol Myers Squibb Co	C-aryl glucoside SGLT2 inhibitors
JP4456768B2 (ja)	2000-02-02	2010-04-28	壽製薬株式会社	Ｃ−配糖体を含有する薬剤
US6627611B2 (en)	2000-02-02	2003-09-30	Kotobuki Pharmaceutical Co Ltd	C-glycosides and preparation of thereof as antidiabetic agents
US6936590B2 (en) *	2001-03-13	2005-08-30	Bristol Myers Squibb Company	C-aryl glucoside SGLT2 inhibitors and method
US6617313B1 (en) *	2002-03-13	2003-09-09	Council Of Scientific And Industrial Research	Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
EP1381619B1 (en)	2002-03-28	2005-01-12	Council of Scientific and Industrial Research	8-(c-beta-d-glucopyranosyl)-7,3',4'-trihydroxyflavone, process of isolation from pterocarpus marsupium and pharmaceutical composition for treatment of diabetes
EP1495019B1 (en)	2002-04-08	2008-07-02	Council of Scientific and Industrial Research	Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
AU2003225244A1 (en)	2002-05-06	2003-11-11	Diakron Pharmaceuticals, Inc.	Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels
TWI254635B (en) *	2002-08-05	2006-05-11	Yamanouchi Pharma Co Ltd	Azulene derivative and salt thereof
PL1609785T3 (pl) *	2003-03-14	2016-07-29	Astellas Pharma Inc	Pochodne c-glikozydowe i ich sole
EA011515B1 (ru)	2003-08-01	2009-04-28	Янссен Фармацевтика Н.В.	Замещенные бензимидазол-, бензтриазол- и бензимидазолон-о-глюкозиды
WO2005012326A1 (en)	2003-08-01	2005-02-10	Tanabe Seiyaku Co., Ltd.	Novel compounds having inhibitory activity against sodium-dependant transporter
EP1679965A4 (en)	2003-08-01	2009-05-27	Janssen Pharmaceutica Nv	SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
RS20060320A (sr)	2003-08-01	2008-08-07	Janssen Pharmaceutica N.V.,	Supstituisani indazol-o-glukozidi
SG130189A1 (en)	2003-08-01	2007-03-20	Janssen Pharmaceutica Nv	Substituted indole-o-glucosides
TWI370818B (en) *	2006-04-05	2012-08-21	Astellas Pharma Inc	Cocrystal of c-glycoside derivative and l-proline
WO2008075736A1 (ja) *	2006-12-21	2008-06-26	Astellas Pharma Inc.	Ｃ－グリコシド誘導体の製造方法及びその合成中間体

2004
- 2004-03-12 PL PL04720254T patent/PL1609785T3/pl unknown
- 2004-03-12 PT PT08012499T patent/PT1980560E/pt unknown
- 2004-03-12 PL PL08012499T patent/PL1980560T3/pl unknown
- 2004-03-12 CN CN2004800067612A patent/CN1802366B/zh not_active Expired - Lifetime
- 2004-03-12 ES ES04720254.4T patent/ES2567571T3/es not_active Expired - Lifetime
- 2004-03-12 EP EP04720254.4A patent/EP1609785B1/en not_active Expired - Lifetime
- 2004-03-12 TW TW097128123A patent/TWI309980B/zh not_active IP Right Cessation
- 2004-03-12 US US10/541,615 patent/US7202350B2/en not_active Expired - Lifetime
- 2004-03-12 KR KR1020087015323A patent/KR101001850B1/ko not_active Expired - Fee Related
- 2004-03-12 EP EP08012499A patent/EP1980560B1/en not_active Expired - Lifetime
- 2004-03-12 RU RU2005131838A patent/RU2317288C3/ru active Protection Beyond IP Right Term
- 2004-03-12 AT AT08012499T patent/ATE510834T1/de active
- 2004-03-12 KR KR1020057017126A patent/KR101001848B1/ko not_active Expired - Lifetime
- 2004-03-12 ZA ZA200507754A patent/ZA200507754B/en unknown
- 2004-03-12 AU AU2004220222A patent/AU2004220222B2/en not_active Ceased
- 2004-03-12 MX MXPA05009356A patent/MXPA05009356A/es active IP Right Grant
- 2004-03-12 BR BRPI0408140A patent/BRPI0408140B8/pt not_active IP Right Cessation
- 2004-03-12 TW TW093106714A patent/TWI310033B/zh not_active IP Right Cessation
- 2004-03-12 JP JP2005503610A patent/JP4222450B2/ja not_active Expired - Lifetime
- 2004-03-12 CA CA002526145A patent/CA2526145C/en not_active Expired - Fee Related
- 2004-03-12 ES ES08012499T patent/ES2363941T3/es not_active Expired - Lifetime
- 2004-03-12 WO PCT/JP2004/003324 patent/WO2004080990A1/ja not_active Ceased
- 2004-03-12 NZ NZ542399A patent/NZ542399A/en not_active IP Right Cessation
2005
- 2005-10-13 NO NO20054713A patent/NO334799B1/no not_active IP Right Cessation
2007
- 2007-02-26 US US11/710,434 patent/US7772407B2/en not_active Expired - Fee Related
2008
- 2008-06-16 AU AU2008202654A patent/AU2008202654B8/en not_active Ceased
- 2008-07-15 US US12/173,614 patent/US7977466B2/en not_active Expired - Fee Related
- 2008-08-29 JP JP2008222927A patent/JP4913104B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
JPWO2004080990A1 (ja)	2006-06-08
JP4913104B2 (ja)	2012-04-11
EP1980560A3 (en)	2008-10-29
KR20060002818A (ko)	2006-01-09
EP1609785A4 (en)	2008-10-22
RU2317288C2 (ru)	2008-02-20
AU2008202654A1 (en)	2008-07-10
MXPA05009356A (es)	2005-12-05
US20090069252A1 (en)	2009-03-12
CA2526145A1 (en)	2004-09-23
AU2008202654B2 (en)	2010-09-23
TWI310033B (en)	2009-05-21
WO2004080990A1 (ja)	2004-09-23
ATE510834T1 (de)	2011-06-15
CA2526145C (en)	2009-11-24
NO20054713D0 (no)	2005-10-13
AU2004220222B2 (en)	2009-10-01
TW200505889A (en)	2005-02-16
TW200901965A (en)	2009-01-16
US7202350B2 (en)	2007-04-10
NO334799B1 (no)	2014-05-26
PL1980560T3 (pl)	2011-11-30
KR20080072933A (ko)	2008-08-07
AU2008202654B8 (en)	2010-10-14
US20070161787A1 (en)	2007-07-12
CN1802366A (zh)	2006-07-12
NZ542399A (en)	2009-01-31
BRPI0408140A (pt)	2006-03-01
AU2004220222A1 (en)	2004-09-23
ES2567571T3 (es)	2016-04-25
ES2363941T3 (es)	2011-08-19
JP2009046489A (ja)	2009-03-05
US7772407B2 (en)	2010-08-10
US20060122126A1 (en)	2006-06-08
EP1609785A1 (en)	2005-12-28
TWI309980B (en)	2009-05-21
NO20054713L (no)	2005-12-14
PT1980560E (pt)	2011-06-29
ZA200507754B (en)	2007-01-31
CN1802366B (zh)	2010-12-22
EP1609785B1 (en)	2016-02-03
EP1980560B1 (en)	2011-05-25
EP1980560A2 (en)	2008-10-15
JP4222450B2 (ja)	2009-02-12
KR101001850B1 (ko)	2010-12-17
RU2317288C3 (ru)	2021-03-10
BRPI0408140B8 (pt)	2018-12-11
KR101001848B1 (ko)	2010-12-17
RU2005131838A (ru)	2006-05-10
US7977466B2 (en)	2011-07-12

Publication	Publication Date	Title
PL1609785T3 (pl)	2016-07-29	Pochodne c-glikozydowe i ich sole
CA2494177A1 (en)	2004-02-12	Azulene derivatives and salts thereof for use as na+-glucose cotransporter inhibitors
YU34404A (sh)	2006-08-17	N-supstituisani derivati pirolidina kao inhibitori dipeptidil-peptidaze iv
MY129023A (en)	2007-03-30	Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
NO20020968L (no)	2002-04-26	Glukopyranosyloksypyrazolderivater, medisinske sammensetninger inneholdende det samme og intermediater forfremstillingen derav
AU2002350191A8 (en)	2003-06-10	Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
EP1541551A8 (en)	2005-11-09	2-cyano-4-fluoropyrrolidine derivative or its salt
NO20055680L (no)	2006-01-11	Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
NO20024424D0 (no)	2002-09-16	Glykopyranosyloksybenzylbenzenderivater, medisinske sammensetninger inneholdende slike, samt intermediater tilfremstilling av derivatene
NO20051209L (no)	2005-04-15	Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk anvendelse derav samt intermediater for samme
BR0206831A (pt)	2004-07-06	Composto, cristal, agente farmacêutico, agentes para profilaxia ou tratamento de diabetes, de complicações diabéticas, de tolerância prejudicada à glucose e de obesidade, inibidor de peptidase, uso de um composto, e, método de produção de um composto
AR032065A1 (es)	2003-10-22	Derivados de glucopiranosiloxipirazol y composicion farmaceutica
TW200505919A (en)	2005-02-16	DPP-IV inhibitors
DK1845095T3 (da)	2011-11-21	1-thio-D-glucitolderivater
IL175762A0 (en)	2008-04-13	Use of substituted 2-aminotetralines for the preventative treatment of parkinson's disease
IL159412A0 (en)	2004-06-01	A synergistic pharmaceutical combination for the prevention or treatment of diabetes
DE60227421D1 (de)	2008-08-14	Rmazeutische zusammensetzung und verwendung davon
TH82746A (th)	2007-02-01	อนุพันธ์เบนโซควิโนลิซีนที่ถูกแทนที่
ATE460838T1 (de)	2010-04-15	Wässrige desinfektionsmittel auf basis von alkylaminverbindungen und aminopolycarbonsäuren
TW200629011A (en)	2006-08-16	Cleaning agent
EP1626044A4 (en)	2008-08-20	NEW PIPERIDINE DERIVATIVE